Early-Middle Stage Knee Osteoarthritis with
Conditions
Interventions
Control group:Oral administration of Erecoxib tablets (0.1g po bid) combined with glucosamine (0.75g po bid) for a course of 3 months
Group A:Experimental group A: On the basis of the control group, Diosimin (specification 0.45g/tablet), 0.45g po bid, was added for 4 weeks
Group B:Experimental group B:On the basis of the control group, Maiguan Fukang Tablets (specification 0.6g/tablet) were added at 2.4g po tid for 4 weeks
Group C:Experimental group C: On the basis of the control group, combination use of diosmin and Maiguan Fukang Tablets, taking the same dose for 4 weeks
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meets the American College of Rheumatology (ACR) classification criteria for primary knee osteoarthritis, grades KL 1-3; 2. Ultrasound examination confirms joint effusion in the affected knee (retropatellar pouch effusion >=5mm); 3. Fully understands the benefits of this study, voluntarily signs the informed consent form, and agrees to cooperate throughout the entire research process;
Exclusion criteria
Exclusion criteria: 1. History of allergy or contraindications to COX-2 inhibitors (celecoxib) or glucosamine 2. Severe diseases of major organs such as heart, liver, or kidneys; or malignant tumors; 3. Use of glucocorticoids, immunosuppressants, or biologics for osteoarthritis within the past 3 months; 4. History of infection, trauma, tumors, or other conditions in the knee joint; 5. Pregnant or lactating women; 6. Patients with psychiatric disorders or those unable to cooperate with the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of fluid accumulation in the knee joint cavity of the affected limb; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS scores; | — |
Countries
China
Contacts
Public ContactSi Haibo
West China Hospital of Sichuan University
Outcome results
None listed